Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Saved in:
| Title: | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. |
|---|---|
| Authors: | Lee MS; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Ryoo BY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Hsu CH; National Taiwan University Hospital, Taipei, Taiwan., Numata K; Yokohama City University Medical Center, Yokohama, Japan., Stein S; Yale School of Medicine, New Haven, CT, USA., Verret W; Genentech, South San Francisco, CA, USA., Hack SP; Genentech, South San Francisco, CA, USA., Spahn J; Genentech, South San Francisco, CA, USA., Liu B; Genentech, South San Francisco, CA, USA., Abdullah H; Genentech, South San Francisco, CA, USA., Wang Y; Genentech, South San Francisco, CA, USA., He AR; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Lee KH; Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: kyunghunlee@snu.ac.kr. |
| Corporate Authors: | GO30140 investigators |
| Source: | The Lancet. Oncology [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. 808-820. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
